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Background: The omental adipose tissue is pathogenetically involved in both type 2 diabetes mellitus (T2D) and
chronic inflammatory bowel diseases (IBD) such as Ulcerative colitis (UC) and Crohn's Disease (CD). Thus,
adipokines secreted from omental adipose tissue might play an important role in these diseases. Omentin
represents a new adipokine expressed in and secreted by omental adipose tissue. Therefore, it was the aim to
investigate the putative role of a newly described sequence missense variation in the human omentin gene.
Methods: The Val109Asp single nucleotide miss-sense polymorphism and the His86His polymorphism in exon-
4 of the omentin gene were newly identified by random sequencing. Only the miss-sense polymorphism was
investigated further. Genotyping was performed by restriction fragment length polymorphism (RFLP) analysis of
amplified DNA fragments. Three different cohorts of well-characterized individuals were included in the study.
114 patients suffering from T2D, 190 patients suffering from IBD (128 with CD and 62 with UC) and 276 non-
diabetic healthy controls without any history for IBD were analyzed.
Results: The following allelic frequencies were determined: controls: Val-allele: 0.26, Asp-allele: 0.74; T2D: Val-
allele: 0.3, Asp-allele: 0.7; IBD: Val-allel: 0.31, Asp-allele: 0.69. UC and CD patients did not differ in regard to the
allelic frequency. Similarly, controls, T2D patients and IBD patients did not show significant differences in
genotype distribution among each other. Disease manifestation and pattern of infestation were not related to
genotype subgroups, neither in CD nor in UC. Furthermore, there was no significant association between
genotype subgroups and anthropometric or laboratory parameters in T2D patients.
Conclusion: Based on sequence comparisons and homology searches, the amino acid position 109 is conserved
in the omentin gene of humans, mice and chimpanzee but is not completely conserved between other omentin
homologous genes. Moreover, position 109 lies outside the fibrinogen domain. Due to these structural features
and based on the present data, the Val109Asp sequence variation is more a single nucleotide polymorphism than
a real disease-causing mutation.
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Background
Adipokines [1] such as leptin, resistin and adiponectin are
currently investigated as potential future drug targets in
type 2 diabetes mellitus (T2D), lipid metabolism,
endothelial dysfunction and inflammatory diseases in
general. Therefore, the discovery of yet unknown adipok-
ines represents a main target in the field of metabolic and
immunological basic research.
In 2003, a new cDNA [2] named "omentin" (gene bank
accession number: AY549722) was described and
reported to be expressed specifically in human omental
adipose tissue. An abstract published in Diabetes in the
year 2003 [3] reported omentin as a new adipokine
secreted from omental adipose tissue. In 2005, the
genomic structure, promoter sequence, exon-intron
organization, predicted amino acid sequence and putative
protein structure and differential expression of omentin
in omental adipose tissue samples obtained from patients
with chronic inflammatory bowel diseases was published
by our group [4]. Based on the predicted amino acid
sequence, we could demonstrate a 100 % homology
between the omentin amino acid sequence and a protein
termed intelectin [4]. Human intelectin was characterized
as a novel soluble lectin that recognizes galactofuranose
in carbohydrate chains of bacterial cell walls [5]. In 2006,
Yang et al. demonstrated that omentin is capable of
enhancing insulin-mediated glucose-uptake in adipocytes
[6]. Furthermore, they found that omentin is predomi-
nantly expressed in visceral but not in subcutaneous adi-
pose tissue, however, with adipose tissue stromal cells
being the main source of omentin [6]. Omentin was also
detectable in human serum by Western blot analysis and
recombinant omentin in vitro did not affect basal but
enhanced insulin-stimulated glucose uptake in human
adipocytes. Although the mechanism is far from clear and
no specific omentin receptor has been described so far,
omentin seems to induce adipocytic Akt (protein kinase)
phosphorylation [6].
Omentin might exert both metabolic and immuno-mod-
ulatory effects. Since T2D is associated with visceral adi-
pose tissue hypertrophy and since this disease has been
regarded as a chronic and low grade state of inflamma-
tion, it seems reasonable to investigate cohorts of patients
suffering from T2D for sequence variations within the
omentin gene. Additionally, omental adipose tissue is
involved in the transmural and intra-abdominal inflam-
matory process observed in Crohn's Disease (CD) [7-9].
These adipose tissue changes in patients with CD are cited
as  fat hypertrophy,  fat wrapping (fat creeping upon the
bowel) or creeping fat and have long been recognized by
surgeons as a phenomenon suitable for delineating the
extent of active disease [7,8]. The identification of a dis-
tinct secretion pattern of adipokines from creeping fat in
CD [10-14] and from mesenteric adipose tissue in chronic
inflammatory bowel diseases (IBD) can be momentarily
considered as work in progress. The characterization of
omental adipose tissue by its highly active secretory prod-
ucts might lead to the discovery of specific discrimination
and activity markers in IBD and might provide future tar-
gets for drug therapy. Based on this, it seems also reason-
able to investigate omentin sequence variations in the
context of chronic inflammatory bowel diseases (IBD)
such as CD and Ulcerative Colitis (UC).
Therefore, it was our aim
- to search for yet unknown missense sequence variations
within the coding sequence of the human omentin gene,
- to determine the allelic frequency of newly discovered
missense single nucleotide polymorphisms in a cohort of
Caucasian patients suffering from T2D and IBD,
- to describe possible associations of genotype subgroups
with standard metabolic parameters and anthropometric
data in T2D and disease manifestation in IBD.
Methods
Study populations
As healthy controls, 276 non-diabetic subjects (110 males
and 166 females) without any history of chronic inflam-
matory bowel diseases were included in the study. Blood
(EDTA-whole blood and serum) was drawn after an over-
night fast. All participating individuals were informed
about the aim of the study and gave informed consent.
The study was approved by the local ethical committee.
The characteristics of the control subjects are summarized
in table 1.
114 patients suffering from a known history of T2D and
190 patients suffering from IBD such as UC or CD were
referred from the endocrinological or gastroenterological
outpatient clinic, respectively (Department of Internal
Medicine I, University Hospital of Regensburg, Germany).
In contrast to CD, UC is not associated with adipose tissue
changes and thus is suitable as a control. The characteris-
tics of the diabetic study cohort (114 patients) are sum-
marized in table 2, the medication is given in table 3. The
characteristics of the patients suffering from chronic
inflammatory bowel diseases are summarized in table 4.
Identification of two new single nucleotide polymorphisms
Recently, we established exon-specific genomic PCR
amplifications for the 8 exons of the human omentin gene
[3]. Using the random sequencing approach of genomic
DNA obtained from healthy individuals, we could iden-
tify two common and yet unpublished single nucleotide
missense polymorphism (SNP). In exon-4, the nucleotideCardiovascular Diabetology 2007, 6:3 http://www.cardiab.com/content/6/1/3
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+326 (numbering relatively to the ATG start codon) is pol-
ymorphic (A/T). Thus, the codon GAC is replaced by GTC
changing the amino acid Asp to Val at position 109. The
second polymorphism identified (His86His) does not
change the amino acid and is located at nucleotide 258
(C/T) within exon-4. This latter SNP was therefore not
investigated further.
PCR-based RFLP analysis of the omentin Val109Asp SNP
In order to investigate, whether this sequence variation is
a real polymorphism according to the Hardy-Weinberg
equilibrium, a PCR-based RFLP (restriction fragment
length polymorphism) analysis was established for a sim-
ple and inexpensive testing of larger cohorts of patients.
Genomic DNA was prepared from whole venous blood
using a commercially available DNA isolation kit (Qia-
gen, Hilden, Germany). A 471 bp DNA fragment was
amplified under standard conditions by genomic PCR
(annealing temperature: 58°C) in a GeneAmp9600R ther-
mal cycler (Perkin Elmer) using the upstream primer 5'-
GAGCCTTTAGGCCATGTCTCT-3' and the downstream
primer 5'-CTCTCCTTCTTCTCCAGCCCAT-3'. The PCR
product was then digested at 37°C by the restriction
enzyme AccI (Roche Mannheim, Germany) and separated
by 3% agarose gel electrophoresis. Within exon-4, the pol-
ymorphic codon GTC encoding Val is part of a AccI recog-
nition site, whereas the codon GAC eliminates the AccI
recognition site. Thus, in RFLP agarose gel electrophoresis
(fig. 1), Val/Val homozygotes show two bands of 274 bp
and 197 bp, Val/Asp heterozygotes show three bands of
471 bp, 274 bp and 197 bp, and Asp/Asp homozygotes
show one single band of 471 bp (fig. 1).
Statistics
For statistical analysis, the SPSS/PC+ statistical software
package was used (SPSS 12.0). Subjects were compared
for differences in anthropometric and biochemical data
according to their genotypes by two tailed Mann-Whitney
or Kruskal-Wallis tests for comparison of two or more
independent samples. For correlation analysis, two tailed
Spearman test was used as well as Pearsons χ2 test for asso-
ciations between classified variables. Data are expressed as
means and standard error of the mean (SEM) for simplic-
ity. A p value below 0.05 (two tailed) was considered to be
statistically significant. Adjustments according to Bonfer-
roni were not done.
Results
Characteristics of the study population
Cohort of non-diabetic controls without a history of IBD
276 non-diabetic control subjects (110 males and 166
females) were included. Table 1 shows the characteristics
of the control subjects. Individuals were comparable with
respect to age and BMI. As a well-known metabolic fea-
Table 2: Characteristics of 114 patients with diabetes mellitus type 2
Total Males Females p
n (%) 114 (100) 68 (59.6) 46 (40.4)
Age (years ± SEM) 62.9 ± 0.9 60.8 ± 1.3 66.2 ± 1.4 * 0.008
BMI (kg/m2 ± SEM) 28.8 ± 0.7 30.3 ± 0.9 26.7 ± 0.9 * 0.016
Diabetes duration (years ± SEM) 7.8 ± 0.8 7.6 ± 1.0 8.1 ± 1.4 ns
HbA1c (% ± SEM) 7.5 ± 0.2 7.6 ± 0.2 7.4 ± 0.3 ns
Cholesterol, total (mg/dl ± SEM) 199 ± 5 196 ± 7 203 ± 7 ns
HDL-cholesterol (mg/dl ± SEM) 49 ± 2 46 ± 2 54 ± 3 * 0.03
LDL-cholesterol (mg/dl ± SEM) 117 ± 5 122 ± 7 110 ± 6 ns
Triglycerides (mg/dl ± SEM) 176 ± 11 188 ± 14 158 ± 15 ns
Uric acid (mg/dl ± SEM) 6.7 ± 0.6 7.3 ± 0.9 5.9 ± 0.4 ns
SEM = standard error of the mean, ns = not significant, * = statistical significance between males and females
Table 1: Characteristics of 276 non-diabetic control subjects.
Total Males Females p
n (%) 276 (100) 110 (39.9) 166 (60.1)
Age (years ± SEM) 38.9 ± 0.9 38.5 ± 1.5 39 ± 1.0 n.s.
BMI (kg/m2 ± SEM) 27.9 ± 0.4 27.8 ± 0.6 28.1 ± 0.6 n.s.
Cholesterol, total (mg/dl ± SEM) 221 ± 3 220 ± 5 223 ± 4 n.s.
HDL-cholesterol (mg/dl ± SEM) 58 ± 1 50 ± 2 62 ± 2 p < 0.0001
LDL-cholesterol (mg/dl ± SEM) 133 ± 3 130 ± 5 134 ± 3 n.s.
Triglycerides (mg/dl ± SEM) 168 ± 15 199 ± 23 151 ± 21 p = 0.03
Uric acid (mg/dl ± SEM) 5.7 ± 0.1 6.8 ± 0.1 4.9 ± 0.1 p < 0.0001
SEM = standard error of the mean, n.s. = not significantCardiovascular Diabetology 2007, 6:3 http://www.cardiab.com/content/6/1/3
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ture, females had significantly higher HDL values (p <
0.0001), lower triglyceride levels (p = 0.03) and lower lev-
els of uric acid (p < 0.0001) than males. All calculations
were repeated with a completely balanced gender relation,
but the results presented in the manuscript were not influ-
enced when data were compared either to the total control
group or to a completely gender-balanced control group.
Cohort of patients suffering from T2D
In total, 114 patients (68 males, 46 females) with a
known history of T2D were included in the study. The
mean age was 62.9 ± 0.9 years, mean BMI was 28.8 ± 0.7
kg/m2 and mean diabetes duration was 7.8 ± 0.8 years.
The detailed characteristics of the entire study population
are summarized in table 2. Both genders were comparable
with respect to mean diabetes duration, medication,
mean HbA1c levels, total cholesterol, LDL-cholesterol,
HDL-cholesterol, triglycerides, uric acid and creatinine.
Females were significantly older (66.2 ± 1.4 vs. 60.8 ± 1.3
years, p = 0.008) and had a lower BMI (26.7 ± 0.9 vs. 30.3
± 0.9 kg/m2, p = 0.016) and higher HDL-cholesterol levels
(54 ± 3 vs. 46 ± 2 mg/dl) than males (table 2).
Age was positively associated with BMI (p = 0.003), pres-
ence of peripheral arterial occlusive disease (p = 0.041),
CRP levels (p = 0.001), and negatively associated with cre-
atinine clearance (p < 0.0001). Diabetes duration was
positively associated with the presence of peripheral neu-
Table 3: Medication in 114 patients with type 2 diabetes mellitus.
Therapy Diabetes Hypertension Lipid-lowering
patients n (%) 114 (100) patients n (%) 88 (77.2) patients n (%) 28 (24.6)
Medications
diet 114 (100)
sulfonylureas 29 (25.4)
metformin 44 (38.6)
glitazones 2 (1.8)
glinides 7 (6.1)
carboanhydrase inhibitors 2 (1.8)
insulin (alone/combined) 52 (45.6)
statins/fibric acid 28 (24.6)
ACE inhibitors 40 (35.1)
calcium-channel blockers 19 (16.7)
diuretic drugs 41 (36.0)
beta-blockers 32 (28.1)
others 3 (2.6)
Since combined therapies are possible, percentages/numbers might exceed 100
Table 4: Study cohort of 190 patients suffering from chronic inflammatory bowel diseases.
Total population Crohn's Disease Ulcerative Colitis
n (%) 190 (100%) 128 (67.4%) 62 (32.6%)
age (years) ± SEM 37 ± 10 36 ± 10 39 ± 10
female n (%) 85 (44.7%) 64 (50.0%) 21 (34%)
male n (%) 106 (55.3%) 64 (50.0%) 42 (66%)
Body mass index (BMI) kg/m2 ± SEM 23.8 ± 3.5 23.3 ± 3.6 24.7 ± 3.2
C-reactive protein mg/dl ± SEM 14.6 ± 13.5 15.1 ± 13.0 13.9 ± 14.4
systemic steroids n (%) 79 (41%) 46 (36%) 33 (53%)
topical steroids n (%) 47 (25%) 24 (18%) 23 (37%)
other immuno-suppressants n (%) 48 (25%) 32 (24%) 16 (25%)
Vienna classification [22] n (%): L1 - 21 (16.4%) -
L2 - 24 (18.8%) -
L3 - 67 (52.3%) -
L4 - 16 (12.5%) -
B1 - 35 (27.3%) -
B2 - 35 (27.3%) -
B3 - 58 (45.4%) -
Vienna classification: L1 = terminal ileum, L2 = colon, L3 = ilecolon, L4 = upper gastrointestinal tract; B1 = non-stricturin, non-penetrating, B2 = 
stricturing, B3 = penetratingCardiovascular Diabetology 2007, 6:3 http://www.cardiab.com/content/6/1/3
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ropathy (p < 0.0001), retinopathy (p = 0.001) and coro-
nary artery disease (p = 0.024). BMI was positively
associated with total cholesterol (p = 0.032), triglycerides
(p = 0.002), LDL-cholesterol (p = 0.013), and negatively
associated with HDL-cholesterol (p = 0.003). Based on
these well known correlations (data not shown), the
present study cohort represents the typical characteristics
of a type 2 diabetic population. The medication of the
patients is shown in table 3.
Cohort of patients suffering from UC or CD
In total, 190 patients (85 females, 106 males) with IBD
were included, 128 suffering from CD and 62 suffering
from UC. The mean BMI was 23.8 ± 3.5 kg/m2 and the
mean CRP level was 14.6 ± 13.5 mg/dl. 41 % of the total
study population were treated with systemic steroids, 25
% with topical steroids and 25 % with other immunosup-
pressants. The detailed study characteristics and the
Vienna classification of patients suffering from Crohn's
disease are given in table 4.
Genotyping and allelic frequency of the Asp109Val SNP 
within exon-4
Cohort of non-diabetic controls without a history of IBD
Out of 276 control subjects, 14 (5.1 %) were homozygous
for the Val/Val genotype, 124 (44.9 %) were heterozygous
for the Val/Asp genotype and 138 (50.0 %) were
homozygous for the Asp/Asp genotype. According to the
Hardy-Weinberg equilibrium, allelic frequency was calcu-
lated to be 0.26 for the Val allele and 0.74 for the Asp
allele. Anthropometric and measured laboratory parame-
ters did not differ significantly between genotype sub-
groups.
Cohort of patients suffering from T2D
Genotyping was successfully performed in all of the 114
patients with T2D (table 5). Out of 114 patients, 12 (10.5
%) were homozygous for the Val/Val genotype, 44 (38.6
%) were heterozygous for the Val/Asp genotype and 58
(50.9 %) were homozygous for the Asp/Asp genotype.
According to the Hardy-Weinberg equilibrium, allelic fre-
quency was calculated to be 0.3 for the Val allele and 0.7
for the Asp allele. Concerning lipid, laboratory and
anthropometric parameters, no significant differences
were found between the three genotype subgroups. More-
over, when combining Val/Asp with Asp/Asp genotypes or
Val/Val with Val/Asp genotypes as one single group, no
significant differences could be found concerning the clin-
ical and laboratory parameters.
Cohort of patients suffering from UC or CD
All 190 patients suffering from IBD were successfully gen-
otyped. Out of these, 17 (8.9 %), were homozygous for
the Val/Val genotype, 82 (43.2 %) were heterozygous for
the Val/Asp genotype and 91 (47.9 %) were homozygous
for the Asp/Asp allele. Accordingly, allelic frequency was
calculated to be 0.31 for the Val allele and 0.69 for the Asp
allele. Genotype distribution of subgroups of patients
with UC and CD are summarized in table 6. No signifi-
cant differences in the genotype distribution and allelic
Genomic PCR-based RFLP analysis of the Val109Asp SNP Figure 1
Genomic PCR-based RFLP analysis of the Val109Asp SNP. λ = DNA molecular weight marker, 1 = Val/Val homozy-
gotes, 2 = Asp/Val heterozygotes, 3 = Asp/Asp homozygotes.
λ 12 3
471 bp
274 bp
197 bpCardiovascular Diabetology 2007, 6:3 http://www.cardiab.com/content/6/1/3
Page 6 of 8
(page number not for citation purposes)
frequencies were found between both subgroups (table 6)
and when compared to control subjects and patients suf-
fering from T2D (data not shown).
Discussion
There are several considerations why it seems reasonable
to investigate omentin sequence variations with respect to
IBD such as UC and CD. First of all, there is increasing evi-
dence showing that omental adipose tissue is actively
involved in the pathogenesis of CD [7,8,12,15]. Transmu-
ral adipose tissue inflammation, commonly cited as
"creeping fat" and omental adipose tissue hypertrophy are
oftenly present in active CD and are associated with the
systemic inflammatory response as measured by C-reac-
tive protein [16]. Moreover, visceral adipose tissue in
patients suffering from CD does secret significantly higher
amounts of adiponectin, macrophage colony stimulating
factor (MCSF), monocyte chemoattractant protein-1
(MCP-1), leptin, and migration inhibitory factor (MIF)
than patients suffering from UC [12]. Most interestingly,
we could demonstrate that omental adipose tissue
obtained from patients suffering from CD do express var-
ying degrees of omentin mRNA [4]. Since omentin and
intelectin were reported to be identical human proteins
[4], it is important to emphasize that intelectin was earlier
shown to represent a new type lectin recognizing galacto-
furanose residues in bacterial cell walls. When combining
the intestinal expression profile of omentin (small and
large intestine, intestinal adipose tissue) with the func-
tional data on the recognition of bacteria-specific compo-
nents in the host, omentin could be involved in intestinal
defense mechanisms in CD. Especially the intestinal adi-
pose tissue has been discussed as a primary barrier against
bacterial translocation in IBD [7,8]. In the present study
we could not find a significantly different allelic frequency
of the Val109Asp SNP in patients suffering from IBD
when compared to healthy controls or T2D patients.
Moreover, we could not demonstrate any associaton of
genotypes with disease manifestation or clinical parame-
ters in these patients. However, these results do not
exclude the putative role of yet unknown omentin
sequence variations in the pathogenesis of IBD and the
descriptive data on omentin expression and function do
encourage to investigate this further.
There are several considerations why it seems reasonable
to investigate omentin sequence variations with respect to
type 2 diabetes mellitus. Omental adiposity [17,18]
preceds the development of insulin resistance and T2D
and is one of the major components of the metabolic syn-
drome. Since adipokines derived from omental adipose
tissue are clearly involved in insulin resistance, dyslipi-
demia and coronary artery disease [1,19-21], new adipok-
ines such as omentin might play an important role in the
pathogenesis of T2D and associated metabolic disorders.
However, in the present study we failed to demonstrate a
significantly different allelic frequency of the Val109Asp
SNP in patients with T2D when compared to healthy con-
trols or patients suffering from IBD. Moreover, we could
not find any associations of the SNP with standard
anthropometric and metabolic parameters. However,
these results do not exclude the putative role of yet
Table 6: Genotype distribution of the Val109Asp SNP in 190 patients suffering from chronic inflammatory bowel diseases
Total population (n = 190) Crohn's Disease (n = 131) Ulcerative Colitis (n = 59) p
Genotype
Val/Val n (%) 17 (8.9) 11 (8.4) 6 (10.1) n.s.
Val/Asp n (%) 82 (43.2) 57 (43.5) 25 (42.4) n.s.
Asp/Asp n (%) 91 (47.9) 63 (48.1) 28 (47.5) n.s.
n.s. not significant between groups
Table 5: Anthropometric parameters and laboratory parameters in genotype subgroups of the omentin Val109Asp SNP (114 patients 
with type 2 diabetes mellitus
Val/Val Val/Asp Asp/Asp p
n (%) 12 (10.5) 44 (38.6) 58 (50.9) n.s.
Age (years) ± SEM 61.2 ± 3 62.7 ± 1.5 63.5 ± 1.5 n.s.
BMI (kg/m2) ± SEM 27.9 ± 1.4 28.1 ± 0.9 29.6 ± 1.1 n.s.
HbA1c (% ± SEM) 7.5 ± 0.4 7.4 ± 0.3 7.7 ± 0.3 n.s.
Cholesterol (mg/dl ± SEM) 197 ± 14 193 ± 9 203 ± 7 n.s.
HDL-cholesterol (mg/dl ± SEM) 45 ± 3 50 ± 3 50 ± 2 n.s.
LDL-cholesterol (mg/dl ± SEM) 122 ± 17 121 ± 8 111 ± 6 n.s.
Triglycerides (mg/dl ± SEM) 216 ± 40 167 ± 18 172 ± 12 n.s.
mean ± SEM, n.s.= not significantCardiovascular Diabetology 2007, 6:3 http://www.cardiab.com/content/6/1/3
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unknown omentin sequence variations in the pathogene-
sis of T2D.
Since the allelic frequency of the Val109Asp SNP does not
differ between healthy controls, T2D patients and patients
suffering from IBD, the amino acid position at 109 might
not be critical for the function of the omentin protein.
However, unless functional studies with site directed
mutagenesis have been performed, it is not possible to
speculate about the functional consequence.
Affinity chromatography using galactose-sepharose and
protein analysis by SDS-PAGE revealed that omentin
forms a 120 kDa homotrimer linked by disulfide bonds
[5]. Since omentin lacks a classical transmembrane
domaine [4,5] and is detectable in human sera, the pro-
tein seems to be a secreted protein. Human omentin con-
tains two potential N-glycosylation sites at Asn154 and at
Asn163 [5], but not at the Val/Asp109 site investigated in
this study (additionally, Val/Asn can not form disulfide
binding sites or a phosphorylation sites). The Val/Asp109
site lays carboxyterminally outside of a fibrinogen
domain spanning from amino acid 38 to amino acid 82.
Amino acid position 109 is conserved between humans,
mice and chimpanzee. However, when compared to the
homologous proteins XCGL (Xenopus laevis cortical gran-
ule lectin), LSL (L. japonica lamprey serum lectin) and
αGSL (H. roretzi ascidian glactose-specific lectin), the site
at position 109 does not represent a completely conserved
consensus amino acid position [5], whereas the direct
adjacent site at 108 contains a highly conserved amino
acid (alanine). Although there do not exist experimental
data on the functional consequence of the Val109Asp
mutation on protein function, the proximity of the
mutated amino acid to the higly conserved amino acid at
site 108 might be of functional relevance.
Since we decided not to investigate the allelilc frequency
of the His86His SNP in our cohort, we cannot exclude
that this SNP might stand in a putative linkage dysequilib-
rium with other gene polymorphisms playing a role in
metabolism. Future studies might address this question.
Conclusion
Based on sequence comparisons, homology searches and
considerations concerning the protein domain structure,
there might be an explanation why the Val109Asp SNP
does not associate with the clinical parameters investi-
gated in our cohort of patients and why allelic frequencies
are very similar between subgroups. However, unless
functional studies have been performed, it is not possible
to speculate about the functional consequence of the
mutation. Based on expressional and functional consider-
ations, additional omentin sequence variations not yet
described should be investigated in cohorts of patients
with T2D or IBD.
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